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Abstract
Background: Network meta-analysis (NMA) allows for the estimation of comparative effectiveness of treatments
that have not been studied in head-to-head trials; however, relative treatment effects for all interventions can only
be derived where available evidence forms a connected network. Head-to-head evidence is limited in many disease
areas, regularly resulting in disconnected evidence structures where a large number of treatments are available. This
is also the case in the evidence of treatments for relapsed or refractory multiple myeloma.
Methods: Randomised controlled trials (RCTs) identified in a systematic literature review form two disconnected
evidence networks. Standard Bayesian NMA models are fitted to obtain estimates of relative effects within each
network. Observational evidence was identified to fill the evidence gap. Single armed trials are matched to act as
each other’s control group based on a distance metric derived from covariate information. Uncertainty resulting
from including this evidence is incorporated by analysing the space of possible matches.
Results: Twenty five randomised controlled trials form two disconnected evidence networks; 12 single armed
observational studies are considered for bridging between the networks. Five matches are selected to bridge
between the networks. While significant variation in the ranking is observed, daratumumab in combination with
dexamethasone and either lenalidomide or bortezomib, as well as triple therapy of carfilzomib, ixazomib and
elozumatab, in combination with lenalidomide and dexamethasone, show the highest effects on progression free
survival, on average.
Conclusions: The analysis shows how observational data can be used to fill gaps in the existing networks of RCT
evidence; allowing for the indirect comparison of a large number of treatments, which could not be compared
otherwise. Additional uncertainty is accounted for by scenario analyses reducing the risk of over confidence in
interpretation of results.
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Background
Network meta-analysis (NMA) has become increasingly
popular among both clinicians and policy makers as a tool
to assess the evidence for new technologies relative to all
available comparator treatments [1]. The technique allows
researchers to estimate the comparative effectiveness of
treatments that have not been studied in head to head tri-
als. However, relative treatment effects for all interven-
tions of interest can only be derived where it is possible to
establish a viable, connected network (see Lu and Ades for
an introduction [2]). Unfortunately, it is often challenging
to find high quality evidence (e.g. RCT) for all potentially
relevant treatments of interest, and as a result evidence
networks may be partial or incomplete.
One option is to conclude that evidence is insufficient
to make a judgement on relative treatment effects.
Often, however, a decision on reimbursement or treat-
ment choice is required and cannot be postponed. One
could rely on clinical judgement to inform the compara-
tive effects, as has been done in the past, however, add-
itional uncertainty is not being accounted for [3].
Recently, novel methods have been proposed as a means
of incorporating evidence from observational studies or
patient level data and thereby potentially overcoming
some of the limitations described above. Hierarchical
models have been proposed to systematically incorporate
comparative observational evidence based on summary
as well as individual patient level data [4–6]. Random
main effects models allow for the incorporation of
before-and-after studies, where access to patient level
data is not a necessity [7]. An alternative is to simultan-
eously synthesise multiple outcome measures and derive
relative effects through a chain of evidence [8]. Complex
methods such as propensity scoring or matching
adjusted indirect comparison make use of individual
patient level data to create a comparison adjusting for
measured covariates [9–13]. The choice of method de-
pends on the data available. RCTs continue to be the
gold standard of evidence. Analyses based on individual
patient level data allow for the adjustment of observed
covariates; however, individual patient level data is quite
often unavailable. Analyses based on summary data are
prone to bias and need to be interpreted with great care.
Multiple myeloma (MM) is the second most common
form of blood cancer with an age-adjusted incidence of
six per 100,000 per year in the USA and Europe [14, 15].
Initial treatment options for MM typically involve corti-
costeroids in combination with other drugs including al-
kylating chemotherapeutic agents and novel biological
drugs, with or without hematopoietic stem cell rescue
[15, 16]. Several, novel biological drugs have demon-
strated promising activity in treating MM including
immunomodulatory drugs (e.g. thalidomide, lenalido-
mide and pomalidomide) and proteasome inhibitors (e.g.
bortezomib and carfilzomib). Yet there continues to
be a substantial unmet clinical need, and at present
there is no cure for MM with relapse remaining inevitable
[17, 18]. Given the poor prognosis for relapsed and refrac-
tory MM (RRMM), there is an immediate demand to es-
tablish effective, evidence-based treatment approaches in
this area of unmet clinical need. Currently, comprehensive
comparative data between treatments and disease stages is
lacking [19]. An assessment of clinical effectiveness across
pharmacological treatments for RRMM is essential in
order to establish how treatments for RRMM compare on
outcomes.
There are a number of non-systematic reviews avail-
able which discuss the utility of available or emerging
treatments for RRMM [17, 20, 21]. Previous systematic
reviews have tended to focus on single drugs [22–25];
few considered survival outcomes and the clinical effect-
iveness of more than one drug intervention for RRMM.
Lopuch et al. [26] used data from four RCTs to evaluate
the safety and efficacy of targeted pharmacological
interventions for RRMM, used as monotherapy or in
combination with other drugs. Dranitsaris and Kuara
offer an indirect comparison of lenalidomide and borte-
zomib specifically using data from three RCTs [27].
However, these papers are limited in scope and do not
encompass the broad variety of active treatments avail-
able for RRMM.
More recently, three more comprehensive analyses
were published. The Institute for Clinical and Economic
Review report on treatments for RRMM presented a
NMA comparing the relative effectiveness of seven in-
terventions using data from randomised and single-arm
studies [28]. Disconnected evidence was linked through
a comparison of two key treatment regimens (bortezo-
mib plus dexamethasone and bortezomib monotherapy)
obtained from a retrospective matched pairs analysis
[29]. Van Beurden-Tan and colleagues obtained relative
effects for 18 treatment options under the assumption of
equal efficacy of bortezomib plus dexamethasone and
bortezomib monotherapy as well as thalidomide plus
dexamethasone and thalidomide monotherapy [3].
Armoiry et al. have recently highlighted the disagree-
ment between published matched pair analyses and the
assumption of equal efficacy applied here [30]. Botta et
al. obtained relative effects across the network by group-
ing regimens into nine groups [31]. An analysis of inde-
pendent treatments is also provided, however, still
assuming equal efficacy of bortezomib monotherapy and
bortezomib plus dexamethasone as well as thalidomide,
thalidomide plus dexamethasone and lenalidomide plus
dexamethasone. None of these analyses incorporated the
additional uncertainty introduced by making assump-
tions of equal efficacy or using estimates obtained
through retrospective analysis.
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The objective of this analysis is to fill the gap in RCT
evidence by utilising additional information from observa-
tional evidence to obtain relative effect estimates of all
treatments for RRMM, while capturing additional uncer-
tainty to avoid over confidence in interpretation of results.
Methods
Literature search and data extraction
A systematic search of the published literature and rele-
vant conference proceedings was conducted to identify
eligible studies and is reported following PRISMA guide-
lines. The review protocol is published in Prospero
(www.crd.york.ac.uk/PROSPERO/display_record.asp?ID
=CRD42014013405). In August 2014, the first search
was carried out in MEDLINE, EMBASE and the
Cochrane Library’s Central Register of Controlled Trials;
the search was updated in January 2016 and February
2017 (RCTs only). Papers were first checked by title, and
then underwent abstract review. Papers were required to
be in English and were included if they presented (a) ori-
ginal studies, (b) clinical effectiveness of any (pharmaco-
logical) intervention for the treatment of RRMM, and (c)
reported progression-free survival (PFS), overall survival
(OS) or time to progression (TTP) as primary or second-
ary outcome. The analysis presented here focuses on
median PFS, study details are therefore restricted to
studies reporting this outcome. Phase I dose-escalation
studies, studies focusing on patient samples with
different or mixed treatment conditions, and studies pre-
senting subgroup analysis of a dataset adopted from a
main clinical trial were excluded. For RCTs, conference
abstracts and presentations were excluded if a corre-
sponding published paper was available or could be
identified snowballing. Conference abstracts for observa-
tional studies were excluded as they were limited in
intervention and outcome information and lacked
evidence of scientific validation. The full electronic search
strategy can be accessed in online under Additional file 1.
The quality of trials included in the NMA was assessed
using the Cochrane risk of bias tool from the Cochrane
handbook for RCTs [32] (ÁM, JL) and an adapted
Newcastle Ottawa Scale (NOS) for observational studies
[33] (JL, NH). Three authors (ÁM, EH, VB) extracted data
on population characteristics, intervention description,
and outcome measures. Estimates of the relative effective-
ness of treatments on the hazard ratio scale, along with a
measure of precision (standard error) were extracted, as
well as median time to event data for each trial arm.
Statistical analysis
RCT only analysis
In a first step, standard Bayesian NMA models were
fitted to analyse RCT evidence only. NMA models pro-
vide a powerful method to synthesize data from multiple
trials and generate estimates of relative efficacy between
treatments within connected networks of evidence, by
combining direct and indirect evidence [34]. Indirect
estimates rely on the assumption of transitivity and the
use of relative effects ensures randomisation is preserved.
Based on median PFS data and patient numbers, the
model estimated the relative efficacy for each pairwise
comparison, measured as hazard ratios (HRs) assuming
an exponential survival model.
For each arm k in study i, a binomial likelihood func-
tion is used to model the number of patients alive at
median time to event ri, k , out of a total number of pa-
tients included in the arm ni, k.
ri;k  bin pi;k ; ni;k
 
Based on the estimated survival probability pi, k the
model estimates the log hazard logai, k using the median
time to event wi, k and assuming an exponential survival
function.
pi;k ¼ 1−expð−wi;k  expðlogai;kÞÞ
Using standard NMA modelling, the model then esti-
mates log hazard ratios compared to baseline treatments
in each trial (δi, k).
logai;1 ¼ μi þ 0
logai;k ¼ μi þ δi;k ; k≠1
PFS was chosen as the preferred outcome as it was
most widely reported among the included trials. TTP
was used where PFS was not reported. Since this paper
focusses primarily on the methodology, no additional
survival outcomes were considered. Median PFS was
used in order to accommodate the incorporation of
observational studies, the majority of which do not re-
port HRs for survival outcomes. The model was fitted in
WinBUGs using the R2Winbugs package in R [35, 36].
A Bayesian approach was taken using non-informative
prior distributions. Fixed effects were assumed due to
the limited amount of trials comparing the same two
interventions. The WinBUGs code is available as
Additional file 2.
Bayesian analyses capture uncertainty in the form of
posterior distributions. We summarised outcomes as
means and 95% credible intervals for hazard ratios. Fur-
ther, we established a ranking of alternative treatments
based on the surface under the cumulative ranking curve
(SUCRA) score [37]. The SUCRA score is defined as the
normalised area under the curve of the cumulative
ranking plot, which shows, for every treatment, the
probability of being the best, among the two best,
among the top three treatments, etc. for the range of
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available treatments. The SUCRA score ranges from 0 to
1, where 1 reflects the best treatment with no uncertainty
and 0 reflects the worst treatment with no uncertainty.
Extending NMA with observational studies
RCT data in this analysis formed two disconnected treat-
ment networks, making comparisons of treatments be-
tween networks impossible using standard techniques.
The aim of incorporating observational data here is to
strengthen the existing RCT data and assist in drawing
comparisons across all treatment interventions.
The analysis limited the inclusion of observational stud-
ies to those investigating at least one intervention, which
was part of the RCT network. This restriction resulted in
the exclusion of all potentially relevant comparative obser-
vational studies, leaving only single armed studies for in-
clusion. In the absence of access to patient level data,
single armed observational trials were matched to act as
each other’s control group based on covariate information.
The inclusion of single armed studies was hence restricted
to those reporting a complete covariate profile. Only stud-
ies investigating different interventions were considered as
potential matched pairs.
A clinical expert in MM provided guidance for identi-
fying and ranking covariates relevant for predicting
treatment outcomes (MOD). Covariates selected in de-
scending order of importance were: Frailty (defined by a
composite of age, Charlson’s comorbidity score (CCS)
and activity daily score (ADS)); genetic risk profile, treat-
ment history, baseline stage and gender. Age was used
as surrogate for frailty, since CCS and ADS were not
generally reported in the trials. Genetic risk profile infor-
mation was also very rarely reported and therefore not
included. Finally, we used treatment history (weight = 4,
measured as the medium number of prior treatments;
normalised assuming a range of 0–4 prior lines), age
(weight = 3, measured as median age, normalised assum-
ing a range of 20–80 as median age), baseline stage
(weight = 2, measured as mean baseline stage, normal-
ised assuming a range of 0–3) and gender (weight = 1,
measured as the proportion of females in each study).
The distance Δtot between any two studies j and k was
determined as the weighted average of differences in
covariates:
Δtot ½ j; k ¼
X4
i¼1
wi  Δi½ j; k
X4
i¼1
wi
Where wi refer to the weights given to individual co-
variates and Δi[j, k] represents the normalised difference
between studies j and k in covariate i. A numerical
example illustrating the process is provided as Add-
itional file 3. The distance takes a value between 0 and
1, where small values indicate more similar trials. There
is no guidance available as to what is an adequate
threshold for similarity; a distance of 0.1 was selected as
the maximum distance allowable for matching study
pairs. The impact of varying the threshold in this
application is reported elsewhere [38]. As a further in-
vestigation into the appropriateness of the threshold we
have compared the distance between observational
studies to distances between and within RCTs.
A base case model was fitted including all matches
connecting the separate networks using the same model-
ling approach as described above. Further, each match
was investigated separately incorporating the RCT
evidence above as well as each match in turn. Investigat-
ing the range of possible matches this way allows for the
evaluation of variation associated with matched trial
approaches.
We validated our method by comparing our analysis
with estimates from previous inter network compari-
sons [3, 29, 31, 39].
Each NMA model discarded 50,000 burn-in iterations
and was run with 100,000 iterations and three chains.
Visual inspection of chains and autocorrelation plots
confirmed convergence and the effective sample size was
checked.
Results
Study details
In total, 2505 papers were identified. After duplicates
were removed, 2195 remaining titles and abstracts were
screened for relevance. Of those, 1466 papers were
excluded leading to 729 studies eligible for full-text read-
ing. In total, 36 RCTs and 114 observational studies ful-
filled the inclusion criteria and were used for data
extraction. The PRISMA diagram is shown in Fig. 1.
Excluding studies which did not report median PFS or
TTP, studies investigating different doses or delivery
methods of the same intervention, as well as observa-
tional studies investigating interventions not part of the
RCT network or with incomplete covariate profile for
single armed studies, resulted in 25 RCTs and 12 obser-
vational studies relevant for the analysis presented here.
Reasons for exclusion of the remaining studies are pre-
sented in Additional file 4.
Demographic information on the trials included in the
analysis is shown in Table 1; the evidence network based
on RCT evidence is shown in Fig. 2.
Study quality
The RCTs were of mixed quality. Many studies were
un-blinded, which created a high risk of bias. Addition-
ally, the majority of studies failed to give sufficient
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information regarding randomisation and allocation con-
cealment to determine the risk of selection bias. In most
cases attrition bias was treated appropriately, and only
one study presented a high risk, while another presented
unclear risk in this regard. All but one of the studies
were subject to high risk of bias due to other factors not
accounted for in the Cochrane tool, such as sponsor
involvement in study design, data collection and analysis
and writing, small sample size, and by being a
conference abstract rather than a full text peer reviewed
paper. The observational studies showed a low risk of
bias, with no study scoring below 4 out of a possible
6 stars. Details on the bias assessment are provided
as Additional file 5.
Analysis of RCTs only
Twenty-five RCTs investigating 25 separate treatment reg-
imens were analysed. Of these regimens, 13 treatment
combinations are currently licensed in Europe. Since com-
parisons of these interventions may be of primary interest,
we have highlighted these in our results.
The combined RCT evidence forms two separate
evidence networks (Fig. 2). Since there was no trial in-
vestigating any of the treatment regimens from the
larger white network with a treatment investigated in
the smaller black network, no comparative estimates be-
tween treatments of separate networks can be obtained.
The analysis was conducted separately for the white and
the black network. Tables 2 and 3 shows the relative
HRs and 95% credible intervals for each within network
comparison.
The SUCRA score shown as the solid line in Fig. 3
provides an additional summary statistic of each
treatment’s overall ranking. Rankograms showing the
probability of each intervention to be ranked best, sec-
ond best etc. are shown in Additional file 6.
Fig. 1 PRISMA flowchart
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Fig. 2 RCT evidence network: Each node represents a treatment regimen and connections between nodes indicate comparative RCT evidence.
Interventions licensed in Europe are highlighted in grey. bev = bevacizumab; bor = bortezomib; carf = carfilzomib; cyc = cyclophosphamide;
dara = daratumumab; dex = dexamethasone; elo = elozumatab; IFN = interferon alpha; ixa = ixazomib; len = lenalidomide; ob = oblimersen; pan =
panobinostat; peri = perifosine; PLD = pegylated liposomal doxorubicin; pom = pomalidomide; sil = silituximab; thal = thalidomide; vor = vorinostat
Table 2 Hazard ratios of progression free survival and 95% credible intervals for within network comparisons based on RCT
evidence only for the white network
Licenced treatments and comparisons between those are highlighted in grey. Significant differences on the 95% credible level are in bold
bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa
ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal
thalidomide, vor vorinostat
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Table 3 Hazard ratios of progression free survival and 95% credible intervals for within network comparisons based on RCT
evidence only for the black network
Licenced treatments and comparisons between those are highlighted in grey. Significant differences on the 95% credible level are in bold
bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa
ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal
thalidomide, vor vorinostat
a b
Fig. 3 SUCRA score for within network comparisons based on RCT evidence only (solid line) and RCT evidence including matches to strengthen
within network evidence (dotted line) ** for a the white and b the black network. *Interventions with a licence in Europe. ** includes match 1
(Table 5) for white and matches 2 and 3 (Table 5) for black network. bev = bevacizumab; bor = bortezomib; carf = carfilzomib; cyc = cyclophosphamide;
dara = daratumumab; dex = dexamethasone; elo = elozumatab; IFN = interferon alpha; ixa = ixazomib; len = lenalidomide; ob = oblimersen; pan =
panobinostat; peri = perifosine; PLD = pegylated liposomal doxorubicin; pom= pomalidomide; sil = silituximab; thal = thalidomide; vor = vorinostat
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Dara+len + dex was estimated to be the best treatment
in the white network with respect to PFS, showing a sig-
nificant improvement (using the 95% credible intervals)
compared to all other treatments in the network. This
combination was followed by the other triple combina-
tions (carf, ixa and elo in combination with len + dex),
among which no significant differences were observed,
which did however, show significant improvements
compared to other licensed treatments with the exception
of bor + PLD. Lowest efficacy was shown by five
unlicensed regimens (pom, thal, dex, ob + dex, thal+IFN),
which have shown significantly lower efficacy compared
to all licensed interventions (with the exception of bor
versus pom). Pom + dex and bor appeared the worst
ranked licensed treatments, showing no significant differ-
ence to non-licensed regimens bor + bev and bor + vor.
Dara+bor + dex was estimated to be the most effica-
cious treatment regimen in the black network showing a
significant improvement over the remaining treatments
except for carf+dex and thal+bor + dex. Three of the
other licensed treatments follow (carf+dex, thal+bor +
dex and bor + dex + pan), as well as elo + bor + dex with
similar efficacy to bor + dex + pan. Lowest efficacy was
shown by two unlicensed regimens (bor + dex + peri and
bor + dex + cyc). No significant difference was found be-
tween the licenced combination bor + dex and any of the
unlicensed regimens.
The rank analysis showed an increased uncertainty of
bor + bev compared to other treatments in the larger
white network (see figure (b) of Additional file 6). This
increased uncertainty is likely due to its connection
through relatively small trials to the remaining regimens.
Similar effects were observed in the black network for a
number of regimens.
Due to the disconnected overall network, it is not
possible to draw any conclusion on between network
comparisons based on RCT evidence alone.
Analysis of RCTs plus observational studies
After removing trials not reporting the relevant outcome
measure or investigating interventions not part of the
RCT network, only single armed evidence was left for
inclusion. Twelve of these studies provided a full covari-
ate profile and were considered for matching. Table 1
summarises the outcomes and baseline characteristics of
these studies. Restricting combinations to matches be-
tween trials investigating different treatment regimens,
there were a total of 56 possible matches. A distance
metric incorporating median age, median number of
prior treatment lines, mean baseline stage and propor-
tion of females was calculated for each possible match;
results are shown in Table 4.
A distance threshold of 0.1 was applied for the base
case analysis, and this resulted in the exploration of 14%
Table 4 Distance metric between observational studies
Matches of within network pairs are shaded in grey. Pairs explored at a threshold of 0.1 are bold and underlined
bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa
ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal
thalidomide, vor vorinostat
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(n = 8) of possible matches, which are underlined and
marked in bold in Table 4. Table 5 summarises these 8
matched studies included in the analysis.
Five studies had no matched pair below the threshold
and were not included in the base case [40–44]. Of the
eight matches explored, one strengthens the within
white network evidence, two the within black network
evidence and five matches connect both networks allow-
ing for a comparison between all treatment regimens.
The evidence network including these 8 matches is
shown in Fig. 4.
We first explored the impact of including matches
strengthening the within network evidence (match 1 for
white and matches 2 and 3 for black network (Table 5)),
matches connecting both networks are explored in a
second step.
The grey dotted line in Fig. 3 shows the SUCRA score
of the first step. The impact of adding a match connect-
ing len + dex and pom + dex in the white network is
minimal indicating that the evidence added does not
contradict the RCT evidence. Due to network properties,
adding matches for the comparative effect of bor + dex
and dex + thal only affects the relative effects of these
regimens as well as bor + dex + thal. The ranking shows
a decrease in SUCRA score for bor + dex + thal as well
as dex + thal; however, one should note that the reorder-
ing in the ranking only affects interventions between
which no significant difference was observed.
The second step analysed the matches connecting
both networks. A model incorporating all five connect-
ing matches was fitted as well as five models investigat-
ing each match in turn.
The relative HRs and 95% credible intervals of com-
parisons between treatments licensed in Europe based
on the model incorporating all five connections is dis-
played in Table 6, the SUCRA plot is shown in Fig. 5.
All pairwise comparisons including those of unlicensed
treatments can be found as Additional file 7.
Dara+len + dex is estimated the most efficacious treat-
ment showing significant improvement compared to all
other licensed interventions. Dara+bor + dex, carf+len +
dex, ixa + len + dex, elo + len + dex and carf+dex follow,
showing no significant differences between each other.
With the exception of carf+dex, these treatments show
superiority over the remaining strategies, with the excep-
tion of thal+bor + dex. Pom + dex, bor and bor + dex
show the least efficacy of all licensed treatments and no
significant differences among each other. In the ranking
of all investigated interventions, eight of the licensed in-
terventions show the highest efficacy and none of the
unlicensed strategies show a significant improvement
over any of the licensed strategies. However, some of the
unlicensed strategies such as elo + bor + dex or bor + bev
appear to have similar effects to many licensed treat-
ment pathways.
The SUCRA score of licensed treatments of all
scenarios individually are shown as Additional file 8.
While the relative ranking of treatments within each
network remains unchanged, considerable variation
on inter-network comparisons is observed. However,
dara+len + dex remains best or second-best treatment
strategy in all scenarios (dara+len + dex is exceeded
by dara+bor + dex in match 8). Dara+bor + dex also
remains in the top 5 treatment strategies in all
scenarios. The triple combinations with len + dex are
also ranked in the top 5, except for scenario 5, where
carf+dex, and triple combinations with bor + dex are
ranked higher.
Table 5 Matches included in base case analysis
ID Match 1 Match 2 Drug 1 Drug 2 PFS 1a PFS 2a HRb
Within white network
1 Hou et al. [73] Lacy et al. [74] dex + len dex + pom 8.3 4.8 0.58
Within black network
2 Fukushima et al. [72] Terpos et al. [78] bor + dex dex + thal 16.8 8 0.48
3 Pantani et al. [76] Terpos et al. [78] bor + dex dex + thal 8.7 8 0.92
Connecting both networks
4 Hou et al. [73] Richardson et al. [77] dex + len bor + dex + pan 8.3 5.4 0.65
5 Lacy et al. [74] Richardson et al. [77] dex + pom bor + dex + pan 4.8 5.4 1.13
6 Oehrlein et al. [75] Pantani et al. [76] dex + len bor + dex 11.6 8.7 0.75
7 Oehrlein et al. [75] Terpos et al. [78] dex + len dex + thal 11.6 8 0.69
8 Fukushima et al. [72] Oehrlein et al. [75] bor + dex dex + len 16.8 11.6 0.69
bev bevacizumab, bor bortezomib, carf carfilzomib, cyc cyclophosphamide, dara daratumumab, dex dexamethasone, elo elozumatab, IFN interferon alpha, ixa
ixazomib, len lenalidomide, ob oblimersen, pan panobinostat, peri perifosine, PLD pegylated liposomal doxorubicin, pom pomalidomide, sil silituximab, thal
thalidomide, vor vorinostat, HR hazard ratio, PFS progression free survival
amedian
bestimated from median PFS assuming exponential survival
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To validate our analysis we compared our outcomes
with those of existing inter network comparisons (see
outcomes summarised in Table 7). While no gold stand-
ard exists, two analyses based on individual patient level
data have estimated the relative effect between bor + dex
and bor with respect to PFS [29, 39] representing the
currently best available evidence. Two recent NMAs
made assumptions based on clinical opinion on the
same comparison. None of the studies significantly fa-
vours either strategy. The two NMAs assume equal
efficacy of both interventions, while both individual
patient level data studies show a tendency favouring
bor + dex. While the point estimate in our study fa-
vours bor, there is a large overlap in the confidence
intervals. Further, our analysis shows the highest vari-
ance in the estimate, which is appropriate given the
risk of matching single armed studies, especially based
on summary data.
The sensitivity of choice of threshold has been evalu-
ated for this application previously [38]. The analysis in-
vestigated the trade-off between strict thresholds, which
would reduce the number of matches explored and
therefore potentially underestimate the uncertainty, and
high thresholds, which may include matches of trials
with very different patient populations. A threshold of
0.1 appeared to explore a reasonable level of uncertainty.
In addition, we analysed the similarity between arms
within RCT trials using the same metric. The analysis
was restricted to those studies which report a full covari-
ate profile for each arm. Results indicate that different
arms of the same study have an average distance of 0.01
ranging from 0.00 to 0.03. This indicates that a threshold
of 0.1 allows for the inclusion of matched pairs which
are less similar compared to different arms within an
RCT. Only match 5 would be considered if a threshold
in line with the distances observed within RCT studies
was applied.
Discussion
The purpose of this analysis was to illustrate how obser-
vational data can be used to link otherwise disconnected
evidence networks and aid the estimation of relative
effectiveness between treatments, which would not be
possible otherwise, while acknowledging and communi-
cating the additional uncertainty associated with such an
approach.
Clinical research into pharmacological interventions
for RRMM is a vast and growing field. The large number
of treatment regimens explored over the years form a
complex evidence structure, for which standard methods
for evidence synthesis fail to produce estimates of rela-
tive efficacy between all treatments.
Previous analyses have attempted to solve the problem
of disconnected networks by grouping regimens and
assuming equal efficacy for each group [3, 31]. While
this approach allows for the estimation of relative effects
across the entire evidence base, the uncertainty
associated with the assumption is not incorporated.
Since grouping is done with the aim of connecting dis-
connected networks, there is likely no clinical evidence
supporting equal efficacy for these interventions. Com-
municating results without incorporating additional
layers of uncertainty bares the risk of overconfident in-
terpretation of results. Two studies have used individual
patient level data to obtain the relative effects between
bor and bor + dex [29, 39]. While such analysis can only
Fig. 4 Evidence network including single armed matches: Each node represents a treatment regimen; solid connections between nodes indicate
comparative RCT evidence, dotted connections indicate single armed matches. Interventions licensed in Europe are highlighted in grey. bev =
bevacizumab; bor = bortezomib; carf = carfilzomib; cyc = cyclophosphamide; dara = daratumumab; dex = dexamethasone; elo = elozumatab; IFN =
interferon alpha; ixa = ixazomib; len = lenalidomide; ob = oblimersen; pan = panobinostat; peri = perifosine; PLD = pegylated liposomal doxorubicin;
pom = pomalidomide; sil = silituximab; thal = thalidomide; vor = vorinostat
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account for observed covariates, such analyses provide
the best available evidence in the absence of RCT evidence.
In the absence of individual patient level data, we
propose the use of study level data to match single
armed trials to fill the gap in RCT evidence.
Optimal matching based on summary data is not new,
see for example the work of Rosenbaum [45]; Jaff et al.
provides a recent example of optimal matching in per-
ipheral artery disease [46]. Since matching based on
study level data is prone to bias, capturing uncertainty is
key. The selection of one optimal match may underesti-
mate the uncertainty associated with the methodology.
We therefore explored the space of possible matches
and the impact different matches have on the results.
While general agreement between scenarios can be
observed (higher ranked treatment in either network
remain among the higher ranked treatments overall),
considerable variation in the rank distribution is ob-
served nevertheless. This variation is translated into an
increased variance of estimates of relative effect between
both networks.
The focus of this article is the methodology applied; the
HRs reported in the results should not be interpreted as
hard point estimates. Our analysis indicates that triple
combinations with daratumumab as well as triple combi-
nations with len + dex provide the highest efficacy relative
to remaining treatments, with respect to PFS. Thal+IFN
shows least effects throughout all scenarios.
Limitations
Median PFS was used to compare all treatment regi-
mens, reflecting the outcome most widely reported
across studies. Analyses of other outcomes, such as
overall survival may have produced different results and
further research should consider additional outcomes of
interest.
Observational studies identified in the initial search
varied in methods, from study design through to out-
come reporting, and ultimately only 12 studies were
considered to supplement RCT evidence. Matching
based on study level information is prone to bias,
making appropriate capturing of uncertainty highly im-
portant. There is no guidance on how similar is “similar
enough”. Using a low threshold may result in the under-
estimation of uncertainty, while a high threshold may re-
sult in matching trials too dissimilar to provide useful
comparisons. While a threshold of 0.1 appears to
provide a reasonable exploration of the associated uncer-
tainty, it is worth noting that differences within RCTs
are much lower. Using the same approach, we have cal-
culated the distance between arms within RCTs included
Fig. 5 SUCRA scores of analyses connecting separate networks of evidence. Shows ranking of model including all connecting matches simultaneously
as well as models investigating each match individually. bev = bevacizumab; bor = bortezomib; carf = carfilzomib; cyc = cyclophosphamide; dara =
daratumumab; dex = dexamethasone; elo = elozumatab; IFN = interferon alpha; ixa = ixazomib; len = lenalidomide; ob = oblimersen; pan =
panobinostat; peri = perifosine; PLD = pegylated liposomal doxorubicin; pom= pomalidomide; sil = silituximab; thal = thalidomide; vor = vorinostat
Table 7 Estimated Mean Hazard Ratio and 95% confidence
interval of bor + dex versus bor comparison in different studies
HR bor + dex versus bor
Dimopoulous 2010 [39] 0.73 (0.52,1.03)*
Dimopoulous 2014 [29] 0.60 (0.35,1.01)
Botta [31] 1 (−)
Van Beurden-Tan [3] 1 (−)
Matched analysis 1.15 (0.77,1.74)
bor bortezomib, dex dexamethasone, HR hazard ratio
*confidence interval estimated using p-value
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in this analysis (where data was available) and the max-
imum distance observed was 0.03.
We only allowed for matching observational studies
with each other to avoid interfering with the RCTs (ei-
ther by duplicating an arm or inserting an extra arm).
Alternative to matching single armed observational evi-
dence with each other, we could have matched observa-
tional studies directly to RCTs or connect RCTs with
each other [7, 47]. The distance metric indicates similar
differences for all approaches (average distance 0.17
(range 0.01–0.48) within RCTs, 0.19 (range 0.02, 0.47)
RCT to observational, 0.20 (range 0.03, 0.47) within
observational); however, considering a larger space of
matches may improve the analysis of variation.
Conclusions
Where RCT evidence alone results in a disconnected
evidence structure, additional information can often be
obtained from observational evidence. This paper pre-
sents a novel approach to establish a ranking of available
treatment regimens in disconnected evidence networks
through the incorporation of observational studies,
taking into account the associated uncertainty of match-
ing single armed trials. Applying this method to RRMM,
we present the relative efficacy of available treatment
regimens, which is not possible to obtain using standard
methods.
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